[go: up one dir, main page]

PL1651249T3 - Zastosowanie kalcytoniny w zapaleniu kości i stawów - Google Patents

Zastosowanie kalcytoniny w zapaleniu kości i stawów

Info

Publication number
PL1651249T3
PL1651249T3 PL04741224T PL04741224T PL1651249T3 PL 1651249 T3 PL1651249 T3 PL 1651249T3 PL 04741224 T PL04741224 T PL 04741224T PL 04741224 T PL04741224 T PL 04741224T PL 1651249 T3 PL1651249 T3 PL 1651249T3
Authority
PL
Poland
Prior art keywords
calcitonin
osteoarthritis
Prior art date
Application number
PL04741224T
Other languages
English (en)
Inventor
Moise Azria
Claus Christiansen
Simon David Bateman
Shoufeng Li
Original Assignee
Novartis Ag
Nordic Bioscience As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1651249(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Nordic Bioscience As filed Critical Novartis Ag
Publication of PL1651249T3 publication Critical patent/PL1651249T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04741224T 2003-07-23 2004-07-22 Zastosowanie kalcytoniny w zapaleniu kości i stawów PL1651249T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48940003P 2003-07-23 2003-07-23
PCT/EP2004/008210 WO2005014031A1 (en) 2003-07-23 2004-07-22 Use of calcitonin in osteoarthritis
EP04741224A EP1651249B1 (en) 2003-07-23 2004-07-22 Use of calcitonin in osteoarthritis

Publications (1)

Publication Number Publication Date
PL1651249T3 true PL1651249T3 (pl) 2013-04-30

Family

ID=34135096

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10177751T PL2316473T3 (pl) 2003-07-23 2004-07-22 Zastosowanie kalcytoniny w chorobie zwyrodnieniowej stawów
PL04741224T PL1651249T3 (pl) 2003-07-23 2004-07-22 Zastosowanie kalcytoniny w zapaleniu kości i stawów

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10177751T PL2316473T3 (pl) 2003-07-23 2004-07-22 Zastosowanie kalcytoniny w chorobie zwyrodnieniowej stawów

Country Status (23)

Country Link
US (3) US7749954B2 (pl)
EP (2) EP2316473B1 (pl)
JP (2) JP4716987B2 (pl)
KR (1) KR101070036B1 (pl)
CN (1) CN1856321B (pl)
AU (2) AU2004262906B2 (pl)
BR (1) BRPI0412265A (pl)
CA (1) CA2532565C (pl)
ES (2) ES2398237T3 (pl)
HK (2) HK1152229A1 (pl)
IL (2) IL173002A (pl)
IS (1) IS8316A (pl)
MA (1) MA27929A1 (pl)
MX (1) MXPA06000807A (pl)
NO (1) NO330867B1 (pl)
NZ (1) NZ544645A (pl)
PL (2) PL2316473T3 (pl)
PT (2) PT2316473E (pl)
RU (1) RU2368390C2 (pl)
TN (1) TNSN06022A1 (pl)
TW (1) TWI343816B (pl)
WO (1) WO2005014031A1 (pl)
ZA (1) ZA200600373B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005080A (es) * 2004-05-27 2005-11-30 Aspid S A De C V Una composicion moduladora de la inflamacion articular cronica a base de colagena-polivinilpirrolidona.
CN101627011A (zh) 2005-09-19 2010-01-13 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
KR20140053419A (ko) 2005-11-17 2014-05-07 노파르티스 아게 약제학적 조성물
PL2059260T3 (pl) 2006-08-31 2014-03-31 Novartis Ag Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego
KR101564114B1 (ko) * 2007-03-02 2015-10-28 노파르티스 아게 칼시토닌의 경구 투여
PT2460515T (pt) * 2007-08-09 2017-04-27 Novartis Ag Composições orais de calcitonina e suas aplicações
CA2704780C (en) 2007-11-02 2014-06-10 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
EP2331072B8 (en) 2008-08-18 2020-08-26 Entera Bio Ltd. Methods and compositions for oral administration of proteins
RU2537181C2 (ru) 2009-03-12 2014-12-27 Нордик Байосайенс А/С Лечение диабета и метаболического синдрома
WO2011067283A1 (en) 2009-12-01 2011-06-09 Novo Nordisk A/S Novel peptidyl alpha-hydroxyglycine alpha-amidating lyases
US20120071410A1 (en) * 2010-09-21 2012-03-22 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
EP3095484B1 (en) 2011-11-02 2018-05-02 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders
BR112014010701A2 (pt) 2011-11-02 2020-06-23 Keybioscience Ag Uso de um peptídeo
DK2825636T3 (da) * 2012-03-16 2020-04-20 Fertility Innovations Ltd Behandling af sædceller
SI3068796T1 (en) 2013-11-14 2018-05-31 Keybioscience Ag Calcitonin mimetics for the treatment of diseases and disorders
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190036903A (ko) 2017-09-28 2019-04-05 (주)휴럼 리트세노라이드를 유효성분으로 하는 염증과 골관절염에 대한 예방 및 치료용 약학 조성물
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
CN108586601B (zh) * 2018-05-14 2021-07-27 四川大学 一种骨靶向性鲑鱼降钙素及其制备方法
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
CN117714967A (zh) 2020-03-02 2024-03-15 奇跃公司 沉浸式音频平台

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US608618A (en) 1898-08-09 Thomas millen
HU203204B (en) 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
JP3501471B2 (ja) * 1992-06-15 2004-03-02 旭化成ファーマ株式会社 カルシトニン類の安定化組成物および安定化法
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
GB9623205D0 (en) * 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ATE288415T1 (de) * 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US20020012459A1 (en) * 2000-06-22 2002-01-31 Chips Brain Co. Ltd. Method and apparatus for detecting stereo disparity in sequential parallel processing mode
EP1313699B1 (en) 2000-08-29 2010-03-10 Biocon Limited 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
JP2004519428A (ja) 2000-10-25 2004-07-02 スミスクライン・ビーチャム・コーポレイション カルシライティック化合物
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
MXPA04001418A (es) 2001-08-17 2004-05-27 Novartis Ag Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides.

Also Published As

Publication number Publication date
KR101070036B1 (ko) 2011-10-04
JP4716987B2 (ja) 2011-07-06
IL227988A (en) 2016-10-31
AU2008202879A1 (en) 2008-07-24
AU2008202879B2 (en) 2012-05-24
IL173002A0 (en) 2006-06-11
KR20060034298A (ko) 2006-04-21
ZA200600373B (en) 2007-01-31
US20140271735A1 (en) 2014-09-18
US20060194722A1 (en) 2006-08-31
IL227988A0 (en) 2013-09-30
AU2004262906B2 (en) 2008-04-03
JP2006528152A (ja) 2006-12-14
BRPI0412265A (pt) 2006-09-05
RU2006105479A (ru) 2007-09-10
NO20060890L (no) 2006-04-24
EP2316473A1 (en) 2011-05-04
IS8316A (is) 2006-02-21
PL2316473T3 (pl) 2014-05-30
ES2398237T3 (es) 2013-03-14
PT1651249E (pt) 2012-12-21
HK1089935A1 (en) 2006-12-15
US8765675B2 (en) 2014-07-01
TNSN06022A1 (en) 2007-10-03
WO2005014031A1 (en) 2005-02-17
CA2532565C (en) 2012-05-08
JP2011121987A (ja) 2011-06-23
NO330867B1 (no) 2011-08-01
HK1152229A1 (en) 2012-02-24
US20100278881A1 (en) 2010-11-04
RU2368390C2 (ru) 2009-09-27
MA27929A1 (fr) 2006-06-01
CN1856321A (zh) 2006-11-01
PT2316473E (pt) 2013-09-20
EP1651249A1 (en) 2006-05-03
EP2316473B1 (en) 2013-08-21
AU2004262906A1 (en) 2005-02-17
IL173002A (en) 2013-09-30
MXPA06000807A (es) 2006-08-23
ES2436152T3 (es) 2013-12-27
NZ544645A (en) 2009-04-30
TW200518769A (en) 2005-06-16
US7749954B2 (en) 2010-07-06
EP1651249B1 (en) 2012-09-12
TWI343816B (en) 2011-06-21
CN1856321B (zh) 2012-10-03
CA2532565A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
HK1152229A1 (en) Use of calcitonin in osteoarthritis
GB0613074D0 (en) Electronic bartering
GB0300641D0 (en) Improvements in or relating to devices
GB0315259D0 (en) Use
GB0317615D0 (en) Improvements in or relating to stairlifts
GB2384704B (en) Improvements in spatulas
GB0317618D0 (en) Improvements in or relating to stairlifts
GB0306367D0 (en) Improvements in or relating to stairlifts
PL376755A1 (pl) Zastosowanie R-10-hydroksy-10,11-dihydrokarbamazepiny w bólach neuropatycznych
GB0302462D0 (en) Improvements in or relating to devices
PL359206A1 (pl) Osobista kompozycja czyszcząca
GB0407556D0 (en) Improvements in or relating to photodection
GB0302741D0 (en) Use
GB2409446B (en) Improvements in or relating to stairlifts
PL379145A1 (pl) Kompozycje i sposoby obejmujące związki gastryny
GB0303363D0 (en) Improvements in or relating to devices
PL359205A1 (pl) Osobista kompozycja czyszcząca
GB0312844D0 (en) Use of compounds in medicine
GB0316757D0 (en) Use
GB0315594D0 (en) Vuv surface treatment
GB0318419D0 (en) Improvements in or relating to devices
GB0302576D0 (en) Improvements in or relating to devices
GB0324811D0 (en) Improvements in magnetopolariscopes
GB0314132D0 (en) Improvements in or relating to turbies
GB0328725D0 (en) Improvements in or relating to stairlifts